Lower prices, higher taxes and fewer drugs paid for by the state could be the new regime for France's pharmaceutical industry when the government details plans in September for 2 billion euros ($2.5 billion) of healthcare savings next year. However, the new Socialist government may sugar the pill with measures to encourage investment in the country's fledgling biotech sector, where its 36 listed companies barely reach a total market capitalisation of 2.3 billion euros.